Selected research
Industry Research
Living Biological Drugs Industry Research Report 2026
Market perspective
The global Living Biological Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Living Biological Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Living Biological Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Living Biological Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Living Biological Drugs include Ardeypharman, Miyarisan Pharmaceutical, Ferring Pharmaceuticals, Seres Therapeutics, Infant Bacterial Therapeutics, Osel, Takeda, AOBiome and Synlogic, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Living Biological Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Living Biological Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Living Biological Drugs Market by Company
Ardeypharman
Miyarisan Pharmaceutical
Ferring Pharmaceuticals
Seres Therapeutics
Infant Bacterial Therapeutics
Osel
Takeda
AOBiome
Synlogic
Finch Therapeutics
Capsugel
Jeneil Biotech
UAS Labs
Biose
Cerbios-Pharma
Inpac Probiotics
NIZO
Winclove Probiotics
BJP Laboratories
Luina Bio
List Labs
MatriSys Bioscience
Living Biological Drugs Segment by Type
Single Strain
Multi Strain
Co-Culture
Living Biological Drugs Segment by Application
Digestive System
Urinary System
Skin System
Living Biological Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Living Biological Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Living Biological Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Living Biological Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Living Biological Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Single Strain
- Multi Strain
- Co-Culture
Applications
- Digestive System
- Urinary System
- Skin System
Companies covered
- Ardeypharman
- Miyarisan Pharmaceutical
- Ferring Pharmaceuticals
- Seres Therapeutics
- Infant Bacterial Therapeutics
- Osel
- Takeda
- AOBiome
- Synlogic
- Finch Therapeutics
- Capsugel
- Jeneil Biotech
- UAS Labs
- Biose
- Cerbios-Pharma
- Inpac Probiotics
- NIZO
- Winclove Probiotics
- BJP Laboratories
- Luina Bio
- List Labs
- MatriSys Bioscience
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Living Biological Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Single Strain
- 2.2.3 Multi Strain
- 2.2.4 Co-Culture
- 2.3 Living Biological Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Digestive System
- 2.3.3 Urinary System
- 2.3.4 Skin System
- 2.4 Assumptions and Limitations
3 Living Biological Drugs Breakdown Data by Type
- 3.1 Global Living Biological Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Living Biological Drugs Forecasted Market Size by Type (2027-2032)
4 Living Biological Drugs Breakdown Data by Application
- 4.1 Global Living Biological Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Living Biological Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Living Biological Drugs Market Perspective (2021-2032)
- 5.2 Global Living Biological Drugs Growth Trends by Region
- 5.2.1 Global Living Biological Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Living Biological Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Living Biological Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Living Biological Drugs Market Dynamics
- 5.3.1 Living Biological Drugs Industry Trends
- 5.3.2 Living Biological Drugs Market Drivers
- 5.3.3 Living Biological Drugs Market Challenges
- 5.3.4 Living Biological Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Living Biological Drugs Players by Revenue
- 6.1.1 Global Top Living Biological Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Living Biological Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Living Biological Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Living Biological Drugs Head Office and Area Served
- 6.4 Global Living Biological Drugs Players, Product Type & Application
- 6.5 Global Living Biological Drugs Manufacturers Established Date
- 6.6 Global Living Biological Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Living Biological Drugs Market Size (2021-2032)
- 7.2 North America Living Biological Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Living Biological Drugs Market Size by Country (2021-2026)
- 7.4 North America Living Biological Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Living Biological Drugs Market Size (2021-2032)
- 8.2 Europe Living Biological Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Living Biological Drugs Market Size by Country (2021-2026)
- 8.4 Europe Living Biological Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Living Biological Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Living Biological Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Living Biological Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Living Biological Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Living Biological Drugs Market Size (2021-2032)
- 10.2 South America Living Biological Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Living Biological Drugs Market Size by Country (2021-2026)
- 10.4 South America Living Biological Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Living Biological Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Living Biological Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Living Biological Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Living Biological Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Ardeypharman
- 12.1.1 Ardeypharman Company Information
- 12.1.2 Ardeypharman Business Overview
- 12.1.3 Ardeypharman Revenue in Living Biological Drugs Business (2021-2026)
- 12.1.4 Ardeypharman Living Biological Drugs Product Portfolio
- 12.1.5 Ardeypharman Recent Developments
- 12.2 Miyarisan Pharmaceutical
- 12.2.1 Miyarisan Pharmaceutical Company Information
- 12.2.2 Miyarisan Pharmaceutical Business Overview
- 12.2.3 Miyarisan Pharmaceutical Revenue in Living Biological Drugs Business (2021-2026)
- 12.2.4 Miyarisan Pharmaceutical Living Biological Drugs Product Portfolio
- 12.2.5 Miyarisan Pharmaceutical Recent Developments
- 12.3 Ferring Pharmaceuticals
- 12.3.1 Ferring Pharmaceuticals Company Information
- 12.3.2 Ferring Pharmaceuticals Business Overview
- 12.3.3 Ferring Pharmaceuticals Revenue in Living Biological Drugs Business (2021-2026)
- 12.3.4 Ferring Pharmaceuticals Living Biological Drugs Product Portfolio
- 12.3.5 Ferring Pharmaceuticals Recent Developments
- 12.4 Seres Therapeutics
- 12.4.1 Seres Therapeutics Company Information
- 12.4.2 Seres Therapeutics Business Overview
- 12.4.3 Seres Therapeutics Revenue in Living Biological Drugs Business (2021-2026)
- 12.4.4 Seres Therapeutics Living Biological Drugs Product Portfolio
- 12.4.5 Seres Therapeutics Recent Developments
- 12.5 Infant Bacterial Therapeutics
- 12.5.1 Infant Bacterial Therapeutics Company Information
- 12.5.2 Infant Bacterial Therapeutics Business Overview
- 12.5.3 Infant Bacterial Therapeutics Revenue in Living Biological Drugs Business (2021-2026)
- 12.5.4 Infant Bacterial Therapeutics Living Biological Drugs Product Portfolio
- 12.5.5 Infant Bacterial Therapeutics Recent Developments
- 12.6 Osel
- 12.6.1 Osel Company Information
- 12.6.2 Osel Business Overview
- 12.6.3 Osel Revenue in Living Biological Drugs Business (2021-2026)
- 12.6.4 Osel Living Biological Drugs Product Portfolio
- 12.6.5 Osel Recent Developments
- 12.7 Takeda
- 12.7.1 Takeda Company Information
- 12.7.2 Takeda Business Overview
- 12.7.3 Takeda Revenue in Living Biological Drugs Business (2021-2026)
- 12.7.4 Takeda Living Biological Drugs Product Portfolio
- 12.7.5 Takeda Recent Developments
- 12.8 AOBiome
- 12.8.1 AOBiome Company Information
- 12.8.2 AOBiome Business Overview
- 12.8.3 AOBiome Revenue in Living Biological Drugs Business (2021-2026)
- 12.8.4 AOBiome Living Biological Drugs Product Portfolio
- 12.8.5 AOBiome Recent Developments
- 12.9 Synlogic
- 12.9.1 Synlogic Company Information
- 12.9.2 Synlogic Business Overview
- 12.9.3 Synlogic Revenue in Living Biological Drugs Business (2021-2026)
- 12.9.4 Synlogic Living Biological Drugs Product Portfolio
- 12.9.5 Synlogic Recent Developments
- 12.10 Finch Therapeutics
- 12.10.1 Finch Therapeutics Company Information
- 12.10.2 Finch Therapeutics Business Overview
- 12.10.3 Finch Therapeutics Revenue in Living Biological Drugs Business (2021-2026)
- 12.10.4 Finch Therapeutics Living Biological Drugs Product Portfolio
- 12.10.5 Finch Therapeutics Recent Developments
- 12.11 Capsugel
- 12.11.1 Capsugel Company Information
- 12.11.2 Capsugel Business Overview
- 12.11.3 Capsugel Revenue in Living Biological Drugs Business (2021-2026)
- 12.11.4 Capsugel Living Biological Drugs Product Portfolio
- 12.11.5 Capsugel Recent Developments
- 12.12 Jeneil Biotech
- 12.12.1 Jeneil Biotech Company Information
- 12.12.2 Jeneil Biotech Business Overview
- 12.12.3 Jeneil Biotech Revenue in Living Biological Drugs Business (2021-2026)
- 12.12.4 Jeneil Biotech Living Biological Drugs Product Portfolio
- 12.12.5 Jeneil Biotech Recent Developments
- 12.13 UAS Labs
- 12.13.1 UAS Labs Company Information
- 12.13.2 UAS Labs Business Overview
- 12.13.3 UAS Labs Revenue in Living Biological Drugs Business (2021-2026)
- 12.13.4 UAS Labs Living Biological Drugs Product Portfolio
- 12.13.5 UAS Labs Recent Developments
- 12.14 Biose
- 12.14.1 Biose Company Information
- 12.14.2 Biose Business Overview
- 12.14.3 Biose Revenue in Living Biological Drugs Business (2021-2026)
- 12.14.4 Biose Living Biological Drugs Product Portfolio
- 12.14.5 Biose Recent Developments
- 12.15 Cerbios-Pharma
- 12.15.1 Cerbios-Pharma Company Information
- 12.15.2 Cerbios-Pharma Business Overview
- 12.15.3 Cerbios-Pharma Revenue in Living Biological Drugs Business (2021-2026)
- 12.15.4 Cerbios-Pharma Living Biological Drugs Product Portfolio
- 12.15.5 Cerbios-Pharma Recent Developments
- 12.16 Inpac Probiotics
- 12.16.1 Inpac Probiotics Company Information
- 12.16.2 Inpac Probiotics Business Overview
- 12.16.3 Inpac Probiotics Revenue in Living Biological Drugs Business (2021-2026)
- 12.16.4 Inpac Probiotics Living Biological Drugs Product Portfolio
- 12.16.5 Inpac Probiotics Recent Developments
- 12.17 NIZO
- 12.17.1 NIZO Company Information
- 12.17.2 NIZO Business Overview
- 12.17.3 NIZO Revenue in Living Biological Drugs Business (2021-2026)
- 12.17.4 NIZO Living Biological Drugs Product Portfolio
- 12.17.5 NIZO Recent Developments
- 12.18 Winclove Probiotics
- 12.18.1 Winclove Probiotics Company Information
- 12.18.2 Winclove Probiotics Business Overview
- 12.18.3 Winclove Probiotics Revenue in Living Biological Drugs Business (2021-2026)
- 12.18.4 Winclove Probiotics Living Biological Drugs Product Portfolio
- 12.18.5 Winclove Probiotics Recent Developments
- 12.19 BJP Laboratories
- 12.19.1 BJP Laboratories Company Information
- 12.19.2 BJP Laboratories Business Overview
- 12.19.3 BJP Laboratories Revenue in Living Biological Drugs Business (2021-2026)
- 12.19.4 BJP Laboratories Living Biological Drugs Product Portfolio
- 12.19.5 BJP Laboratories Recent Developments
- 12.20 Luina Bio
- 12.20.1 Luina Bio Company Information
- 12.20.2 Luina Bio Business Overview
- 12.20.3 Luina Bio Revenue in Living Biological Drugs Business (2021-2026)
- 12.20.4 Luina Bio Living Biological Drugs Product Portfolio
- 12.20.5 Luina Bio Recent Developments
- 12.21 List Labs
- 12.21.1 List Labs Company Information
- 12.21.2 List Labs Business Overview
- 12.21.3 List Labs Revenue in Living Biological Drugs Business (2021-2026)
- 12.21.4 List Labs Living Biological Drugs Product Portfolio
- 12.21.5 List Labs Recent Developments
- 12.22 MatriSys Bioscience
- 12.22.1 MatriSys Bioscience Company Information
- 12.22.2 MatriSys Bioscience Business Overview
- 12.22.3 MatriSys Bioscience Revenue in Living Biological Drugs Business (2021-2026)
- 12.22.4 MatriSys Bioscience Living Biological Drugs Product Portfolio
- 12.22.5 MatriSys Bioscience Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst